The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Canada India Tech Council, in partnership with Consulate General of India (Toronto) and TheAppLabb, is proud to announce the ...

VEOCELtm, the flagship specialty nonwovens brand of Lenzing Group, highlighted its commitment to innovation and providing solutions to help address the global plastic crisis at the "SEA of Solutions ...